Immuneering (IMRX) Competitors $3.50 -0.27 (-7.05%) As of 02:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. ARVN, ETON, SVRA, PVLA, ITOS, SNDL, CGEM, CMPS, KOD, and TECXShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Arvinas (ARVN), Eton Pharmaceuticals (ETON), Savara (SVRA), Palvella Therapeutics (PVLA), iTeos Therapeutics (ITOS), SNDL (SNDL), Cullinan Therapeutics (CGEM), COMPASS Pathways (CMPS), Kodiak Sciences (KOD), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Its Competitors Arvinas Eton Pharmaceuticals Savara Palvella Therapeutics iTeos Therapeutics SNDL Cullinan Therapeutics COMPASS Pathways Kodiak Sciences Tectonic Therapeutic Immuneering (NASDAQ:IMRX) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Is IMRX or ARVN more profitable? Immuneering has a net margin of 0.00% compared to Arvinas' net margin of -19.47%. Arvinas' return on equity of -12.01% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -146.28% -117.22% Arvinas -19.47%-12.01%-6.97% Does the media prefer IMRX or ARVN? In the previous week, Arvinas had 1 more articles in the media than Immuneering. MarketBeat recorded 13 mentions for Arvinas and 12 mentions for Immuneering. Immuneering's average media sentiment score of 0.57 beat Arvinas' score of 0.07 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend IMRX or ARVN? Immuneering currently has a consensus target price of $13.25, suggesting a potential upside of 279.11%. Arvinas has a consensus target price of $19.76, suggesting a potential upside of 172.14%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Arvinas.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has more volatility & risk, IMRX or ARVN? Immuneering has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Which has better earnings and valuation, IMRX or ARVN? Immuneering has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K396.68-$61.04M-$1.89-1.85Arvinas$263.40M2.02-$198.90M-$1.01-7.19 Do institutionals and insiders hold more shares of IMRX or ARVN? 67.7% of Immuneering shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 4.7% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryImmuneering and Arvinas tied by winning 8 of the 16 factors compared between the two stocks. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.94M$3.13B$5.72B$9.77BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-1.8520.9330.9025.26Price / Sales396.68231.60403.8188.28Price / CashN/A41.5625.2228.45Price / Book2.639.749.516.00Net Income-$61.04M-$54.74M$3.26B$265.34M7 Day Performance8.88%7.94%4.48%2.84%1 Month Performance-15.38%7.52%5.19%1.58%1 Year Performance239.32%17.41%31.75%25.40% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.5813 of 5 stars$3.50-7.0%$13.25+279.1%+265.0%$126.94M$320K-1.8560Earnings ReportUpcoming EarningsARVNArvinas3.8756 of 5 stars$6.59+4.8%$19.76+199.9%-71.5%$461.80M$263.40M-6.52420ETONEton Pharmaceuticals2.5784 of 5 stars$17.05-0.5%$29.67+74.0%+322.8%$459.65M$39.01M-106.5620SVRASavara3.1288 of 5 stars$2.70+2.3%$5.60+107.4%-30.1%$456.29MN/A-5.6220News CoverageEarnings ReportAnalyst UpgradePVLAPalvella Therapeutics2.8699 of 5 stars$41.71+2.0%$52.40+25.6%N/A$452.18M$42.81M-3.45N/ANews CoverageEarnings ReportAnalyst ForecastITOSiTeos Therapeutics2.804 of 5 stars$10.11flat$15.50+53.3%-32.3%$446.92M$35M-2.1690SNDLSNDL2.2123 of 5 stars$2.01+19.3%$4.00+99.5%-9.0%$441.46M$671.81M-7.432,516High Trading VolumeCGEMCullinan Therapeutics1.5293 of 5 stars$7.09-2.9%$30.00+323.1%-54.2%$430.95MN/A-2.2030Analyst ForecastCMPSCOMPASS Pathways2.677 of 5 stars$4.34-1.1%$16.29+275.2%-38.1%$421.18MN/A-2.36120KODKodiak Sciences3.1626 of 5 stars$8.03+1.6%$9.00+12.1%+327.9%$416.83MN/A-2.2190News CoverageEarnings ReportAnalyst ForecastTECXTectonic Therapeutic2.1166 of 5 stars$22.11-0.9%$80.33+263.3%+38.1%$416.58MN/A-5.47120 Related Companies and Tools Related Companies ARVN Alternatives ETON Alternatives SVRA Alternatives PVLA Alternatives ITOS Alternatives SNDL Alternatives CGEM Alternatives CMPS Alternatives KOD Alternatives TECX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access